[go: up one dir, main page]

Nokin et al., 2024 - Google Patents

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

Nokin et al., 2024

View HTML @Full View
Document ID
501398454331675363
Author
Nokin M
Mira A
Patrucco E
Ricciuti B
Cousin S
Soubeyran I
San José S
Peirone S
Caizzi L
Vietti Michelina S
Bourdon A
Wang X
Alvarez-Villanueva D
Martínez-Iniesta M
Vidal A
Rodrigues T
García-Macías C
Awad M
Nadal E
Villanueva A
Italiano A
Cereda M
Santamaría D
Ambrogio C
Publication year
Publication venue
Nature communications

External Links

Snippet

Selective KRASG12C inhibitors have been developed to covalently lock the oncogene in the inactive GDP-bound state. Two of these molecules, sotorasib and adagrasib, are approved for the treatment of adult patients with KRASG12C-mutated previously treated advanced non …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Similar Documents

Publication Publication Date Title
Nokin et al. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Rosen et al. The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
Echeverria et al. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer
Decarvalho et al. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma
Annunziato et al. Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
Picco et al. Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening
von Loga et al. Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer
Chang et al. Accelerating discovery of functional mutant alleles in cancer
Bertotti et al. The genomic landscape of response to EGFR blockade in colorectal cancer
Hodgkinson et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
Jäkel et al. Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability
Jiang et al. Predictors of chemosensitivity in triple negative breast cancer: an integrated genomic analysis
Ma et al. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer
Felsenstein et al. New developments in the molecular mechanisms of pancreatic tumorigenesis
Durinikova et al. Targeting the DNA damage response pathways and replication stress in colorectal cancer
Schulz et al. Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X
Lin et al. Genomic and transcriptomic alterations associated with drug vulnerabilities and prognosis in adenocarcinoma at the gastroesophageal junction
Yao et al. Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC
Zhou et al. Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence
Park et al. Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling
Pham et al. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers
Kostyrko et al. UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma
Goh et al. Clonal evolutionary analysis during HER2 blockade in HER2-positive inflammatory breast cancer: a phase II open-label clinical trial of afatinib+/-vinorelbine
Rodriguez-Calero et al. Alterations in homologous recombination repair genes in prostate cancer brain metastases
Nastase et al. Integrated genomics point to immune vulnerabilities in pleural mesothelioma